Canada marijuana sellers defiant despite police crackdown

A woman smokes a large joint before The Global Marijuana March in TorontoBy Ethan Lou TORONTO (Reuters) – Operators of Toronto&;s unlicensed marijuana stores said on Tuesday they would defy Canada&039;s drug laws and continue their sales despite a police crackdown two weeks ago that targeted nearly half of the city&039;s roughly 100 stores. Representatives from industry associations and at least 35 medical marijuana stores met to discuss how to keep selling as Canada moves toward legalizing the drug&039;s recreational use. Medical marijuana is legal in Canada, though selling directly to the public is not.

Go to Source

Rugby-Wallabies prop Robinson hangs up boots due to eye injury

Former Australia prop Benn Robinson has retired from rugby due to complications with a serious eye injury when playing for the New South Wales Waratahs in Super Rugby. The popular 72-test forward suffered an accidental poke in the eye during a line-out against the ACT Brumbies in April and had developed a condition called microscopic hyphema, in which blood cells appear in front of the lens, affecting vision. “Rugby has been part of my life for so many years that for it to end like this is just so disappointing.” The 31-year-old said he feared he might suffer from blurred vision for the rest of his life.
Go to Source

Sanofi and Regeneron report positive skin disease trial

French multinational pharmaceutical company SANOFI logo is seen at the headquarters in ParisFrench drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals. "These are the first long-term Phase 3 data that demonstrated dupilumab with topical corticosteroids was superior to topical corticosteroids alone, and provided sustained efficacy, significantly improving measures of overall disease severity, skin clearing, itching, and quality of life through one year of treatment," Regeneron Chief Scientific Officer George D. Yancopoulos said in a statement. Sanofi said in the statement that the partners planned their first submission for regulatory approval for the treatment in the United States in the third quarter of this year.

Go to Source

1 69 70 71 72 73 125